Vinorelbine tartrate (Navelbine) is a new semisynthetic vinca alkaloid with efficacy against a variety of solid tumors, including non-small-cell lung cancer, breast cancer, head and neck cancer, and Hodgkin's lymphoma. Recently approved by the FDA for the first-line treatment of advanced non-small-cell lung cancer, vinorelbine is also under review by the FDA for use in patients with metastatic breast cancer. There is now extensive data confirming the activity of vinorelbine in metastatic breast cancer, with second-line response rates of 17% to 36% and first-line response rates of 40% to 44%. Investigators have combined vinorelbine with other active drugs against breast cancer to produce response rates exceeding 50% for first-line therapy. Numerous centers are now conducting randomized trials comparing vinorelbine to established second-line therapies for advanced breast cancer, such as paclitaxel (Taxol). Future research is needed to further define the precise role of vinorelbine as a component of combination therapy for metastatic breast cancer.
Vinorelbine tartrate (5'-noranhydro-vinblastine) is a new semisynthetic vinca alkaloid with a broad spectrum of in vitro antitumor activity demonstrated in preclinical studies. Phase I/II trials confirmed the efficacy of this drug against a variety of solid tumors, including non-small-cell lung cancer, breast cancer, head and neck cancer, and Hodgkin's lymphoma. Favorable phase III trial results led to its recent FDA approval for use as a first-line agent in ambulatory patients with advanced non-small-cell lung cancer.
After nearly a decade of clinical trials in Europe and recent studies in the United States, there is now extensive data confirming the activity of vinorelbine for metastatic breast cancer. Vinorelbine differs from other vinca alkaloids, for the drug possesses unique pharmacokinetics and a more favorable side-effect profile. This article will review the encouraging results of single agent and combination therapy trials, compare vinorelbine activity to established therapies for breast cancer, consider novel routes of administration, and discuss ongoing randomized clinical trials and future studies that may lead to the widespread use of vinorelbine for the treatment of breast cancer.
The chemical structure of vinorelbine differs from the other members of the vinca alkaloid family (such as vincristine or vinblastine), in that vinorelbine has a substitution on the catharine ring of the molecule instead of the vindoline nucleus. This difference imparts the unique biochemical properties of the drug, and vinorelbine pharmacokinetics thus differ from the other vinca alkaloids.
Vinorelbine is highly lipophilic, which results in more significant tissue uptake and a greater therapeutic index than the other vinca alkaloids. The excretion of vinorelbine following a dose of 30 mg/m² infused over 15 to 20 minutes has been described as triphasic, with a large volume of distribution, high systemic clearance, and prolonged terminal phase due to the slow efflux of the drug from peripheral tissue compartments . The terminal half-life of vinorelbine is 27.7 to 43.6 hours, and the mean plasma clearance ranges from 0.83 to 1.26 L/h/kg [2,3].
Metabolism and Elimination
Vinorelbine is metabolized predominantly by the liver, with most of the drug and its metabolites eliminated via the biliary tract and excreted in feces. In fact, the clearance of vinorelbine approaches hepatic blood flow (1.3 L/h/kg) . Renal clearance accounts for only 10% to 12% of total drug elimination . To date, the effect of hepatic or renal dysfunction on vinorelbine metabolism has not been determined, but dose reduction is recommended for patients with liver function abnormalities.
The hepatic cytochrome P-450 3A enzyme system appears to be responsible for the metabolism of vinorelbine, all vinca alkaloids, and the majority of chemotherapeutic agents [4-6]. One vinorelbine metabolite, deacetylvinorelbine, has been detected in plasma and possesses antitumor activity . Specific drugs have been shown to inhibit vinorelbine metabolism by competitive inhibition of P-450 3A, especially other vinca alkaloids and drugs such as doxorubicin, methotrexate, and calcium-channel blockers [4-6].
Research has demonstrated large variation between patients in the pharmacokinetics of vinorelbine, but the reasons for this diversity are unknown. Although age does not appear to influence vinorelbine pharmacokinetics , there is growing evidence that the activity of the P-450 3A enzyme may be altered with menopause . As a result, investigators are currently studying the potential impact of menopausal status on vinorelbine metabolism.
Potential Mechanisms of Resistance
Like other vinca alkaloids, vinorelbine resistance is presumably mediated by multidrug resistance (MDR) and P-glycoprotein overexpression, which results in enhanced drug efflux from tumor cells [8,9]. The precise mechanism of resistance to vinorelbline has yet to be determined, but the role of MDR is supported by evidence that there appears to be substantial cross-resistance between vinorelbine and other members of the vinca family, as well as a variety of other MDR substrates .
Vinorelbine inhibits microtubule assembly, and thus, is cell-cycle-specific. Like other vinca alkaloids, vinorelbine blocks formation of the mitotic spindle apparatus at metaphase and prevents cell division. This is in contrast to the taxanes, such as paclitaxel (Taxol), which promote and stabilize the assembly of microtubules after spindle formation has occurred.
One of the most promising aspects of vinorelbine relates to this selective effect on microtubules. Peripheral neuropathy is common with most vinca alkaloids, and is believed to result from a direct effect on the microtubules in peripheral nerves. However, in vitro immunofluorescence experiments have demonstrated that vinorelbine is selective for nonneural microtubules . Additional studies have confirmed that toxicity against axonal microtubules typically occurs at a significantly higher vinorelbine concentration (30 to 40 mol/L) than is required for maximal antitumor effect (5 mol/L) [11,12]. Therefore, as expected from preclinical data, vinorelbine has a wide therapeutic window, which has resulted in reduced neurotoxicity in clinical trials compared to the other vinca alkaloids.
Extensive clinical studies have been conducted to elucidate the safety profile of vinorelbine.
Table 1 lists the major toxiciticies of vinorelbine reported in three North American clinical trials involving 222 women with metastatic breast cancer [13,14].
The majority of the adverse events reported in these trials were hematologic. Neutropenia was the most commonly reported toxicity, with 96% of women having an absolute neutrophil count (ANC) < 2,000/mm³ with single-agent treatment and 41% of women experiencing an ANC < 500/mm³. Fever and neutropenia were reported in 9% of treatment cycles. Recovery from hematologic toxicity is rapid, with nadirs typically occurring at 7 to 10 days and complete recovery 1 to 2 weeks later in most cases.
Although neutropenia remains the most frequent cause of dose adjustment or treatment delay in patients who receive weekly vinorelbine administration, growth factor support has not been routinely recommended for weekly 30-mg/m² doses of vinorelbine when used as a single agent. However, combination regimens that include vinorelbine may require granulocyte colony-stimulating factor (G-CSF; filgrastim [Neupogen]) to minimize this additive toxicity and to maintain the dosage schedule.
Vinorelbine also resulted in mild anemia in clinical trials, with 87% of women with breast cancer having a hemoglobin of less than 11 mg/dL. Despite the frequency of this adverse effect, however, transfusion was seldom necessary. Finally, thrombocytopenia was rarely reported; fewer than 10% of administered cycles were associated with platelet counts below 100,000/mm³.
In contrast to its significant myelosuppression, vinorelbine is associated with only modest nonhematologic toxicity. The drug produced mild elevations of serum liver function tests, with abnormal serum glutamic-oxaloacetic transaminase (SGOT) noted more commonly than an increased total bilirubin. However, clinical symptoms or frank hepatic toxicity has not been reported.
Vinorelbine is only mildly emetogenic, and coadministration of potent serotonin antagonist antiemetics is not routinely required. The predominant gastrointestinal side effects included nausea (50%), vomiting (23%), constipation (38%), and diarrhea (20%).
Vinorelbine is a mild vesicant, and local reactions involving phlebitis or pain at the infusion site were reported in approximately 20% of patients. Peripheral neuropathy, characterized by mild to moderate, reversible paresthesias or hypoesthesias, occurred in 30% of women. No grade III or grade IV neurotoxicity was seen, and loss of deep-tendon reflexes was noted in fewer than 5% of patients.
Dyspnea occurred in 9% of patients within hours after vinorelbine administration, and yet pulmonary symptoms were rarely severe and most likely represent an allergic reaction. Finally, alopecia was reported in 12% of women.
In summary, vinorelbine is well tolerated, with the major toxicity involving neutropenia.
1. Wargin W, Lucas VS: The clinical pharmacokinetics of vinorelbine (Navelbine). Semin Oncol 21(5, suppl 10):21-27, 1994.
2. Krikorian A, Breillout F: Vinorelbine (Navelbine): A new semisynthetic vinca alkaloid. Onkologie 14:7-12, 1991.
3. Rahmani R, Bruno R, Athanassios I, et al: Clinical pharmacokinetics of the antitumor drug Navelbine (5¢-noranhydrovinblastine). Cancer Res 47:5796-5799, 1987.
4. Kumar G, Walle UK, Walle T: Cytochrome P-450 3A-mediated human liver microsomal Taxol 6 alpha-hydroxylation. J Pharmacol Exp Ther 268(3):1160-1165, 1993.
5. Zhou-Pan X, Sérée E, Zhou XJ, et al: Involvement of human liver cytochrome P-450 3A in vinblastine metabolism: Drug interactions. Cancer Res 53:5121-5126, 1993.
6. Zhou XJ, Zhou-Pan X, Gauthier T, et al: Human liver microsomal cytochrome P-450 3A isozymes mediated vindesine biotransformation. Biochemical Pharmacol 45(4):853-861, 1993.
7. Gustavson L, Benet LZ: Menopause: Pharmacodynamics and pharmacokinetics. Exp Gerontol 29(3/4):437-444, 1994.
8. Burris H, Fields S: Summary of data from in vitro and phase I vinorelbine (Navelbine) studies. Semin Oncol 21(5, suppl 10):14-20, 1994.
9. Adams D, Knick V: MDR and non-MDR forms of cellular resistance to 5-noranhydrovinblastine (Navelbine) (abstract). Proc Am Assoc Cancer Res 33:462, 1992.
10. Zhou XJ, Rahmani R: Preclinical and clinical pharmacology of vinca alkaloids. Drugs 44(suppl 4):1-16, 1992.
11. Binet S, Fellous A, Lataste H, et al: In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 16(2, suppl 4):5-8, 1989.
12. Cvitkovic E, Izzo J: The current and future place of vinorelbine in cancer therapy. Drugs 44(suppl 4):36-45, 1992.
13. Hohneker J: A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 21(5, suppl 10):42-47, 1994.
14. Hohneker J: Navelbine in breast cancer: Safety profile. Burroughs Wellcome Drug Information Department, p 2, 1994.
15. Marty M, Extra JM, Dieras V, et al: A review of the antitumour activity of vinorelbine in breast cancer. Drugs 44 (suppl 4):29-35, 1992.
16. Hortobagyi GN: Overview of new treatments for breast cancer. Breast Cancer Res Treat 21:3-13, 1992.
17. Mathé G, Reizenstein P: Phase I pharmacologic study of a new vinca alkaloid: Navelbine. Cancer Lett 27:285-293, 1985.
18. Canobbio L, Boccardo F, Pastorino G, et al: Phase II study of Navelbine in advanced breast cancer. Semin Oncol 16(2 suppl 4):33-36, 1989.
19. Dieras V, De Cremoux P, Extra J, et al: A two stage phase II study of vinorelbine in patients with previously treated advanced breast cancer (abstract). Breast Cancer Res Treat 14:146, 1989.
20. Gasparini G, Caffo O, Barni S, et al: Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: A phase II study. J Clin Oncol 12(10):2094-2101, 1994.
21. Weber B, Vogel C, Jones S, et al: A U.S. multicenter phase II trial of Navelbine in advanced breast cancer. Proc Am Soc Clin Oncol 12:61, 1993.
22. Fumoleau P, Delgado FM, Delozier T, et al: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11(7):1245-1252, 1993.
23. Romero A, Rabinovich MG, Vallejo CT, et al: Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12(2):336-341, 1994.
24. Bruno S, Lira-Puerto V, Texeira L, et al: Phase II trial with vinorelbine (Navelbine) in the treatment of advanced breast cancer (ABC) (abstract 268a). Ann Oncol 3(suppl 1):126, 1992.
25. Jones S, Winer E, Vogel C, et al: A multicenter, randomized trial of IV Navelbine vs IV Alkeran in patients with Anthracycline-refractory advanced breast cancer. Proc Am Soc Clin Oncol 13:103, 1994.
26. Spielman M, Dorval T, Turpin F, et al: Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 12:9:1764-1770, 1994.
27. Hochster H, Vogel C, Blumenreich M, et al: A multicenter phase II study of Navelbine and doxorubicin as first line chemotherapy of metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 13:100, 1994.
28. Chadjaa M, Izzo J, Levin F, et al: Preliminary data on epirubicin-vinorelbine: A new active combination in advanced breast cancer. (abstract 1281). Amer Assoc Cancer Res 33:214, 1992.
29. Ferrero JM, Wendling JL, Hoch M, et al: Mitoxantrone (MTZ)-vinorelbine (VNR) as first line chemotherapy in metastatic breast cancer: A pilot study. Proc Am Soc Clin Oncol 12:108, 1993.
30. Smalley R, Craig J, Jones S, et al: Navelbine and Adriamycin in combination for advanced breast cancer phase I-II evaluation of a new schedule. Proc Am Soc Clin Oncol 13:89, 1994.
31. Dieras V, Pierga J, Extra JM, et al: Results of a combination of Navelbine (NVB) and fluorouracil (FU) in advanced breast cancer (ABC) patients using a group sequential design (GSD). Ann Oncol 3(suppl 5):46, 1992.
32. Scheithauer W, Kornek G, Haider K, et al: Effective second line chemotherapy of advanced breast cancer with Navelbine and mitomycin C. Breast Cancer Res Treat 26:49-53, 1993.
33. Knick VC, Eberwein DJ, Miller CG: Preclinical activity of Navelbine and Taxol drug combinations (abstract). Amr Assoc Cancer Res 35:327, 1994.
34. Adams DJ: Synergy of Navelbine-Taxol combination treatment in two human breast cancer cell lines (abstract). Amer Assoc Cancer Res 35:377, 1994.
35. Dittrich C, Zifko U, Fazeny B, et al: Vinorelbine after paclitaxel in breast cancer: Cross resistance and cumulative neurotoxicity? Ann Oncol 5(5):473-474, 1994.
36. Fazeny B, Zifko U, Meryn S, et al: Navelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel (abstract 29). Proc Am Soc Clin Oncol 13:57, 1994.
37. Winer E, O'Rourke M, Vogel C, et al: A US multicenter phase II trial of oral Navelbine in elderly women with advanced breast cancer (abstract). Breast Cancer Res Treat 27:136, 1993.
38. Rowinsky E, Noe D, Trump D, et al: Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol 12(9):1754-1763, 1994.
39. Favre R, Delgado M, Besenval M, et al: Phase I trial of escalating doses of oral Navelbine (NVB): Part II-Clinical results. Proc Am Soc Clin Oncol 8:64, 1989.
40. Pinedo H, van Groeningen C: Vinorelbine: A horse of a different color. J Clin Oncol 12(9):1745-1747, 1994.
41. Toussaint C, Izzo J, Spielmann M, et al: Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol 12(10):2102-2112, 1994.